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Abstract Hearing loss has been recognized as an important
cause of morbidity in infants with Pompe disease, a
metabolic disorder caused by deficiency of acid α-
glucosidase. It is unknown whether hearing is also affected
in adult Pompe patients. We have studied the prevalence,
severity, and type of hearing loss in 58 adult patients using
tympanometry and pure-tone audiometry. Compared to
normative data (International Organisation for Standardisa-
tion standard 7029), 72% of patients had impaired
hearing thresholds at one or more frequencies in at least
one ear. All measured frequencies were equally affected.
All patients had a sensorineural type of hearing loss,
pointing to cochlear or retrocochlear pathology. Categor-
ised according to the standards of the World Health
Organisation 21% of patients had a clinically relevant
hearing loss (16% slight, 3% moderate, 2% profound).
Though this suggests that hearing loss occurs in a
considerable number of patients with Pompe disease, this
prevalence is similar to that in the general population.
Therefore, we conclude that hearing loss is not a specific
feature of Pompe disease in adults.
Introduction
Pompe disease (also called Glycogen Storage Disease type
II or acid maltase deficiency) (OMIM 232300) is a
lysosomal storage disorder caused by deficiency of the
enzyme acid α-glucosidase (EC 3.2.1.3). This deficiency
results in lysosomal glycogen accumulation, leading to a
multi-system disorder affecting virtually all body tissues in
patients with the classic infantile phenotype, or to a more
slowly progressive disease mainly affecting skeletal and
respiratory muscle function in older children and adults
(Hirschhorn and Reuser 2001; van der Ploeg and Reuser
2008; Laforêt et al. 2000; Wokke et al. 2008).
Hearing deficits have been reported in several lysosomal
storage diseases, including Fabry disease, Gaucher disease
and the Mucopolysaccharidoses (Bamiou et al. 2001;
Campbell et al. 2003; Hegemann et al. 2006; Keilmann et
al. 2009; Komura et al. 1998;P e c k1984; Schachern et al.
1989). In Pompe disease, hearing loss is increasingly
recognised as an important cause of morbidity in patients
with the classic infantile phenotype. So far, auditory
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DOI 10.1007/s10545-011-9396-3function has been described in the literature for 22 classic
infantile Pompe patients. Sixteen of these 22 patients had a
hearing deficit (Kamphoven et al. 2004; Kishnani et al.
2006; Klinge et al. 2005; Rohrbach et al. 2010; van Capelle
et al. 2010a). The observation of glycogen storage in the
cells of the organ of Corti in knock-out mice with Pompe
disease suggests that cochlear pathology is the main cause
of the hearing impairment (Kamphoven et al. 2004). In
older children with Pompe disease, hearing problems are
sporadically present (van Capelle et al. 2010a). In two
related studies on late-onset / adult-onset Pompe disease
four patients were mentioned to have hearing impairment,
but the problem was not studied systematically, and it is as
yet unknown whether hearing impairment occurs more
frequently in adults with Pompe disease than in the general
population (Müller-Felber et al. 2007; Schoser et al. 2007).
It is quite possible that hearing problems develop only after
a prolonged period of time in patients who have residual
enzyme activity.
Since the introduction of enzyme replacement therapy
with alglucosidase alfa (Myozyme®, Genzyme Corpora-
tion) the perspective of patients with Pompe disease has
changed (Chakrapani et al. 2010; Kishnani et al. 2007;
Strothotte et al. 2009; van Capelle et al. 2010b; Van den
Hout et al. 2001; van der Ploeg et al. 2010; Winkel et al.
2004). Today, the focus is not exclusively on the most
limiting aspects of the disease such as reduced mobility and
impaired respiration, but it has also shifted towards other
aspects that may influence the quality of life. Increased
awareness can lead to earlier detection of hearing loss and
timely hearing rehabilitation. Therefore, we studied the
prevalence, severity, and type of hearing impairment in a
cohort of 58 Dutch adults with Pompe disease who are
followed in our centre.
Patients and methods
Patients and procedures
Data were obtained between October 2004 and August
2009 as part of an ongoing nationwide study in the
Netherlands on the natural course of Pompe disease. All
patients were seen at Erasmus MC University Medical
Center. Patients were recruited through neuromuscular
centres within the Netherlands, or through the Dutch
neuromuscular patient organisation. The study was ap-
proved by the Central Committee on Research Involving
Human Subjects in the Netherlands (CCMO). All patients
provided written informed consent. At the time of the
investigation, none of the patients received enzyme re-
placement therapy.
Hearing assessment
The hearing examination comprised tympanometry and
pure-tone audiometry. Pure-tone audiometry was recorded
using a Madsen OB822 clinical audiometer (Copenhagen,
Denmark) and standard TDH 39 earphones with MX41-AR
cushions. Air conduction thresholds and bone conduction
thresholds were obtained for each ear at 0.25, 0.5, 1, 2, 4
and 8 kHz according to a standardised protocol (Interna-
tional Organisation for Standardisation (ISO) 8253–1)
(International Organisation for Standardisation 1989). All
audiometric tests were performed by an experienced
audiologist. Hearing thresholds were considered abnormal
if they were below the 95th percentile of the predicted
value using normative data from the ISO standard 7029 for
comparison (International Organisation for Standardisation
2000). Conductive hearing loss was considered to be
present in case of an air-bone gap of more than 7.5 dB
averaged over the frequencies 0.5 to 2 kHz.
To indicate expected difficulty with conversational
speech, the guidelines of the World Health Organisation
(WHO) on physical functioning, disability and health were
used to grade the severity of the hearing impairment.
Hearing loss was defined as a pure-tone average (PTA) of
thresholds at 0.5, 1, 2 and 4 kHz greater than 25 dB hearing
level. The ears were classified as better-hearing or worse-
hearing depending on this average score. The severity of
hearing loss was categorised as slight (26–40 dB), moderate
(41–60 dB), severe (61–80 dB) or profound (>81 dB) based
on this pure-tone average (World Health Organisation
2001).
Additional clinical information
The following information was available: age at symptom
onset,ageatdiagnosisofPompedisease,diseaseduration,use
of walking devices or wheelchair, use of ventilatory support,
and type of mutation. The presence of contributing medical,
genetic or environmental conditions such as noise exposure,
exposure to chemicals, or use of ototoxic medication was
evaluated by means of a self-reported questionnaire.
Statistical analysis
Continuous variables are presented using mean, median,
standard deviation or range. For categorical variables
percentages or frequencies are given. Differences in
contributing factors between the groups of patients with
and without hearing impairment were tested by χ
2 analyses.
Analyses were performed with SPSS for windows (version
15.0, SPSS Inc., Chicago, IL). A p-value of ≤ 0.05 was
considered significant.
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Study population
Fifty-eight adults with Pompe disease (29 males, 29
females) were included in the study. The mean age at the
time of investigation was 50.5 years (SD 12.5, range 26–
76 years). The mean age at which first neuromuscular
symptoms had manifested, considered as disease onset, was
31.7 years (SD 11.1), and the mean age at diagnosis was
40.7 years (SD 12.8). Disease duration at the time of the
investigation ranged from 1 to 48 years (median 18.9 years).
Six patients had experienced their first symptoms in
childhood or adolescence, at the ages of 1, 10, 11, 15, 16,
or 18 years, of whom only the patient who had symptoms
in the first year of life had been diagnosed before
adulthood. At the time of the hearing investigation, this
patient, now 29 years of age, has only mild skeletal muscle
weakness and does not need ventilatory support. Eight
patients (14%) used walking devices, 21 (36%) were
wheelchair dependent, and 18 (31%) used mechanical
ventilatory support. Three patients (5%) had hearing aids.
Fifty-seven patients had the common c.-32-13 T > G
(IVS1-13 T > G; leaky splice) mutation, combined with a
second pathogenic mutation on the other allele. One patient
had genotype c.671 G > A / c.525del (p.Arg224Gln / p.
Glu176fsX45).
Hearing assessment by pure-tone audiometry
and tympanometry
Sixteen of the 58 patients (28%) had normal hearing levels
for both ears at all frequencies, as measured by pure-tone
audiometry. We found abnormal hearing levels in 42
patients (72%): 22 patients had abnormal hearing thresholds
in both ears, and 20 patients in one ear. All measured
frequencies were equally affected (p=0.63). Figure 1a and
b show the hearing thresholds at all frequencies for the
individual patients compared to the normative values for
age, stratified by gender.
With regard to functional hearing impairment, as
assessed by means of self-reported questionnaires, one of
the 16 patients with normal hearing thresholds reported
difficulty hearing. Of the 42 patients with abnormal hearing
thresholds, 14 reported hearing difficulties.
Tympanometry was abnormal in 20 patients (34%): nine
had slightly negative middle ear pressures, 11 had abnormal
static admittance. However, a significant contribution (air-
bone gap of more than 7.5 dB averaged over the
frequencies 0.5 to 2 kHz) of these conductive abnormalities
to the total amount of hearing impairment was present in
three patients only: one patient had a perforated eardrum,
one had otitis media, and the other one had stiffening of the
bony middle-ear structures. The other 39 patients (93%)
had a pure sensorineural type of hearing impairment.
Grading of hearing impairment according
to the WHO guidelines
Since abnormalities at one or two of the measured
frequencies might not be of clinical importance to the
patient, we also graded the hearing impairment accord-
ing to the WHO guidelines, which better reflects the
severity of the hearing loss (Table 1). Regarding the
better-hearing ear of each patient, 12 of the 58 patients
(21%) had hearing loss: 16% of these patients had slight
hearing loss, 3% moderate hearing loss, and 2% profound
hearing loss. Each of these 12 patients had bilateral
hearing loss. Based on assessments of the worse-hearing
ear, 20 of the 58 patients had some level of hearing loss
(34%). Among these 20 patients are the 12 patients with
bilateral hearing loss and an additional eight patients with
unilateral hearing loss. For comparison, Table 1 also
shows the frequency of hearing loss in the general
population, as graded according to the WHO guidelines,
stratified by age.
Contributing factors
Twenty of the 42 patients with abnormal hearing thresholds
reported medical, genetic or environmental conditions that
may have contributed to the degree of their hearing
abnormality. Reported were: noise exposure (eight
patients), frequent middle ear infections during childhood
(seven patients), familial occurrence of hearing loss (six
patients), use of intravenous aminoglycoside antibiotics
(five patients), diabetes mellitus (two patients), and use of
acetylsalicylic acid (two patients). The proportion of
patients reporting possible contributing factors did not
differ between the group of patients with abnormal hearing
thresholds and the group of patients with normal hearing
thresholds (p=0.70).
Discussion
We studied the prevalence, severity, and type of hearing
loss in adults with Pompe disease to see whether it is an
important cause of morbidity in adults, as it is in infants
with Pompe disease.
With regard to the prevalence of hearing loss, we found
that abnormal hearing thresholds were frequently present
among adults with Pompe disease, but that a clinically
relevant hearing loss was present in 21% of patients only.
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the prevalence in the general population, matched for age
and gender (Davis 1989; Johansson and Arlinger 2003;
Wilson et al. 1999). The severity of hearing loss was
categorised as slight in 16%, moderate in 3%, and profound
in 2%. Fifty percent of the patients with abnormal hearing
thresholds, reported factors such as concomitant disease,
noise exposure or use of ototoxic medication, which may
be responsible for a certain degree of hearing loss.
Unfortunately, it could not be determined to what extent
these factors contributed to the observed hearing impairment.
Of the patients with normal hearing, the same proportion
reported exposure to these conditions.
In all patients in whom we observed hearing loss, we
found a sensorineural type of hearing impairment. Only
three patients (7%) also had significant conductive abnor-
malities, despite the fact that one third of patients had
slightly impaired middle ear function. Therefore, the impact
of middle ear dysfunction on the overall severity of hearing
loss is presumably small.
Hearing loss in Pompe disease was first recognised in
patients with the classic infantile phenotype, when it
became evident that these patients could survive beyond
the age of one year, if they were treated with recombinant
human acid α-glucosidase (Amalfitano et al. 2001;K i s h n a n i
et al. 2007; Van den Hout et al. 2001). Information on the
precise cause of the hearing loss in Pompe disease is scarce.
One study showed raised auditory brainstem response
thresholds in nine of 11 infantile patients, whereas mild
abnormalities in inter-peak latency times were seen in five
(van Capelle et al. 2010a). Another study reported on flat
oto-acoustic emission (OAE) and abnormal wave latencies in
brainstem auditory evoked response (BAER) in some
infants, pointing to inner ear or auditory nervous system
pathology or to both (Kishnani et al. 2006). A study in
knock-out mice with Pompe disease led to the discovery of
glycogen deposition in the inner hair cells and the outer hair
cells of the cochlea, the supporting cells, the stria vascularis,
and the spiral ganglion cells (Kamphoven et al. 2004). These
findings suggest that cochlear pathology rather than involve-
ment of the central auditory nervous system could be the
main cause of the hearing loss. In the present study, we did
not investigate auditory brainstem responses. However, since
the underlying metabolic defect in adults and infants is the
same, the presence of retrocochlear pathology as the primary
cause of the hearing impairment in adults with Pompe
disease is less likely. The observation that profound hearing
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Fig. 1 Hearing thresholds in 29 females (a) and 29 males (b) with
Pompe disease stratified by age. The shaded area represents the 95
percent confidence interval for normal hearing (ISO 7029). The
connected lines represent the pure-tone audiograms of the individual
patients for the right and left ear; each patient within an age group is
represented by a different symbol (×, △, ▲, ▽, ▼, ◆, ◇, ●, ○, ■,o r□)
R
J Inherit Metab Dis (2012) 35:335–341 339impairment is present in nearly every patient with classic
infantile Pompe disease, but only sporadically in older
children and adults is probably due to the higher amount of
residual α-glucosidase activity in the latter groups of
patients, preventing generalised glycogen storage.
Duetothedevelopmentofinnovativetherapeuticmeasures
and higher standard of care, the perspective of patients with
Pompe disease has changed over the last years (Strothotte et
al. 2009; van der Ploeg et al. 2010). It is to be expected that
the focus will not exclusively be on the most threatening
aspects of the disease such as severe muscle weakness and
respiratory failure, but will shift towards other aspects that
influence the quality of life of patients with Pompe disease.
In light of these changing perspectives it is important to
conclude that, unlike in infants, clinically relevant hearing
loss is not a hallmark of Pompe disease in adults. Therefore,
standard screening for hearing impairment does not seem
indicative in adult-onset Pompe disease.
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